intravenous immunoglobulins

Summary

Summary: Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA.

Top Publications

  1. ncbi Intravenous immunoglobulins in the treatment of dengue illness
    Senaka Rajapakse
    Faculty of Medicine, University of Colombo, Colombo 8, Sri Lanka
    Trans R Soc Trop Med Hyg 103:867-70. 2009
  2. ncbi Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association
    Jane W Newburger
    Circulation 110:2747-71. 2004
  3. ncbi Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation
    Yoshikatsu Kaneko
    Laboratory of Molecular Genetics and Immunology, Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Science 313:670-3. 2006
  4. pmc Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease
    R C Dodel
    Department of Neurology, Friedrich Wilhelms University, Sigmund Freudstr 25, 53105 Bonn, Germany
    J Neurol Neurosurg Psychiatry 75:1472-4. 2004
  5. ncbi Intravenous immunoglobulins promote skin allograft acceptance by triggering functional activation of CD4+Foxp3+ T cells
    Thanyalak Tha-In
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Transplantation 89:1446-55. 2010
  6. ncbi Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide
    Gili Istrin
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    J Neurosci Res 84:434-43. 2006
  7. ncbi Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice
    David Ben-Nathan
    Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel
    J Infect Dis 188:5-12. 2003
  8. pmc Clinical uses of intravenous immunoglobulin
    S Jolles
    Department of Clinical Immunology, Royal Free Hospital London, UK
    Clin Exp Immunol 142:1-11. 2005
  9. ncbi Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome
    Donato Rigante
    Department of Pediatric Sciences, Universita Cattolica Sacro Cuore, Largo A Gemelli, 8, 00168, Rome, Italy
    Rheumatol Int 30:841-6. 2010
  10. ncbi Intravenous immunoglobulins induce CD32-mediated platelet aggregation in vitro
    A Pollreisz
    Department of Surgery, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Br J Dermatol 159:578-84. 2008

Detail Information

Publications247 found, 100 shown here

  1. ncbi Intravenous immunoglobulins in the treatment of dengue illness
    Senaka Rajapakse
    Faculty of Medicine, University of Colombo, Colombo 8, Sri Lanka
    Trans R Soc Trop Med Hyg 103:867-70. 2009
    ..manifestations of severe dengue together with the potentially beneficial immunomodulatory effects of intravenous immunoglobulins (IVIG) suggest a possible place for treatment with this expensive therapy...
  2. ncbi Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association
    Jane W Newburger
    Circulation 110:2747-71. 2004
    ..Coronary artery aneurysms or ectasia develop in approximately 15% to 25% of untreated children and may lead to ischemic heart disease or sudden death...
  3. ncbi Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation
    Yoshikatsu Kaneko
    Laboratory of Molecular Genetics and Immunology, Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Science 313:670-3. 2006
    ..This differential sialylation may provide a switch from innate anti-inflammatory activity in the steady state to generating adaptive pro-inflammatory effects upon antigenic challenge...
  4. pmc Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease
    R C Dodel
    Department of Neurology, Friedrich Wilhelms University, Sigmund Freudstr 25, 53105 Bonn, Germany
    J Neurol Neurosurg Psychiatry 75:1472-4. 2004
    ..This study reports the results from a pilot study using IVIgG in patients with AD...
  5. ncbi Intravenous immunoglobulins promote skin allograft acceptance by triggering functional activation of CD4+Foxp3+ T cells
    Thanyalak Tha-In
    Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Transplantation 89:1446-55. 2010
    b>Intravenous immunoglobulins (IVIg) therapy is effective as a treatment for T-cell-mediated immune diseases, but whether and how IVIg suppress allogeneic T-cell responses is largely unknown.
  6. ncbi Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide
    Gili Istrin
    Department of Molecular Microbiology and Biotechnology, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    J Neurosci Res 84:434-43. 2006
    ..Thus, several mechanisms can be considered when examining the effects of IVIg. Our work supports the hypothesis that IVIg interferes by more than one mechanism in clearing AbetaP from the brains of Alzheimer's patients...
  7. ncbi Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice
    David Ben-Nathan
    Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel
    J Infect Dis 188:5-12. 2003
    ..These results indicate that antibodies play a major role in protection and recovery from WNV infection and that IVIG can be used as first-line therapy...
  8. pmc Clinical uses of intravenous immunoglobulin
    S Jolles
    Department of Clinical Immunology, Royal Free Hospital London, UK
    Clin Exp Immunol 142:1-11. 2005
  9. ncbi Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome
    Donato Rigante
    Department of Pediatric Sciences, Universita Cattolica Sacro Cuore, Largo A Gemelli, 8, 00168, Rome, Italy
    Rheumatol Int 30:841-6. 2010
    Clues to predict the response to intravenous immunoglobulins (IVIG) and the development of coronary artery abnormalities (CAA) in children with Kawasaki syndrome (KS) are still undefined...
  10. ncbi Intravenous immunoglobulins induce CD32-mediated platelet aggregation in vitro
    A Pollreisz
    Department of Surgery, Medical University of Vienna, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Br J Dermatol 159:578-84. 2008
    b>Intravenous immunoglobulins (IVIg) and cytomegalovirus immunoglobulins (CMVIg) are currently finding increased acceptance in clinical states of high immune activity and in transplant recipients...
  11. ncbi Polyreactive autoantibodies purified from human intravenous immunoglobulins prevent the development of experimental autoimmune diseases
    Martine Bruley-Rosset
    Laboratoire Francais du Fractionnement et des Biotechnologies, Les Ulis, France
    Lab Invest 83:1013-23. 2003
    b>Intravenous immunoglobulins (IVIg) are therapeutic preparations of normal human polyclonal Ig G (IgG) that exert immunomodulatory effects in patients with autoimmune or systemic inflammatory diseases...
  12. ncbi Immunoglobulin failure and retreatment in Kawasaki disease
    K Durongpisitkul
    Division of Pediatric Cardiology, Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Prannok Road, Bangkok, Thailand 10700
    Pediatr Cardiol 24:145-8. 2003
    ..6% of our Kawasaki patients. We found that low hemoglobin (<10 G/DL), high neutrophil count (> 75%), high band count, and a low albumin were associated with the requirement for retreatment with a second dose of IVIG...
  13. ncbi Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease
    Chih Lu Wang
    Division of Allergy and Immunology, Chang Gung Children s Hospital at Kaohsiung, Chang Gung University, Niau Sung, Kaohsiung, Taiwan
    Pediatrics 111:E140-7. 2003
    ..Kawasaki disease (KD) is an acute febrile vasculitic syndrome in children. CD40 ligand (CD40L) has been implicated in certain types of vasculitis. We proposed that CD40L expression might be correlated with coronary artery lesions in KD...
  14. ncbi Therapeutic activities of intravenous immunoglobulins in multiple sclerosis involve modulation of chemokine expression
    Nadine Pigard
    BMT Research GmbH, Vienna, Austria
    J Neuroimmunol 209:114-20. 2009
    ..We suggest that the modulation of chemokine expression in peripheral T cells contributes to the beneficial activity of IVIG in patients with MS exacerbation...
  15. ncbi 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
    Norman R Relkin
    Department of Neurology, the Weill Cornell Medical College, New York, NY, USA
    Neurobiol Aging 30:1728-36. 2009
    ..Spottke, A., Nolker, C., Moller, H.J., Wei, X., Farlow, M., Sommer, N., Oertel, W.H., 2004. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol...
  16. ncbi Smallpox vaccination and adverse reactions. Guidance for clinicians
    Joanne Cono
    Bioterrorism Preparedness and Response Program, National Center for Infectious Diseases, USA
    MMWR Recomm Rep 52:1-28. 2003
    ..asp. Physicians at military medical facilities can request VIG or cidofovir by calling the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) at 301-619-2257 or 888-USA-RIID...
  17. ncbi Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders
    P Imbach
    Pediatric Hematology Oncology, University Children s Hospital, Medical Faculty of University of Basel, Basel, Switzerland
    Vox Sang 98:385-94. 2010
    ..Controlled clinical and laboratory studies may follow based on new, validated patient selection criteria and focused on mechanisms of action, leading to more evidence-based indications...
  18. ncbi S100A12 (EN-RAGE) in monitoring Kawasaki disease
    Dirk Foell
    Department of Paediatrics, University Hospital Munster, Von Esmarch Str 58, 48149, Munster, Germany
    Lancet 361:1270-2. 2003
    ..0001). Since the interaction of S100A12 with multiligand receptors has a key role in inflammatory responses, this protein could serve as a novel target for future therapeutic interventions in inflammatory disorders...
  19. pmc Intravenous immunoglobulins--understanding properties and mechanisms
    A Durandy
    Inserm U768, Universite Paris Descartes, Hospital Necker, Paris, France
    Clin Exp Immunol 158:2-13. 2009
    ..These findings demonstrate the considerable progress that has been made in understanding the mechanisms of action of IVIgs, and may influence future perspectives in the field of Ig therapy...
  20. ncbi Landau-Kleffner syndrome and CSWS syndrome: treatment with intravenous immunoglobulins
    Willem F M Arts
    Department of Paediatric Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
    Epilepsia 50:55-8. 2009
    ..It might also reflect the natural course of the disease. Although the temporal relation between IVIg treatment and clinical improvement cannot be denied in individual patients, its real value remains to be determined...
  21. ncbi Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis
    A Hamdan
    Internal Medicine B, Rabin Medical Center, Beilinson Campus, Petach Tikva 49100, Israel
    Transpl Infect Dis 4:160-2. 2002
    ..This is the second case of an immunosuppressed patient responding to the same preparation of intravenous immunoglobulins. Larger studies are required in order to establish the therapeutic role of immunoglobulins in patients ..
  22. pmc Resistance to intravenous immunoglobulin in children with Kawasaki disease
    Adriana H Tremoulet
    Department of Pediatrics, University of California San Diego School of Medicine and Rady Children s Hospital San Diego, San Diego, CA, USA
    J Pediatr 153:117-21. 2008
    ..To explore the increased incidence of intravenous immunoglobulin- (IVIG) resistance among San Diego County patients with Kawasaki disease (KD) in 2006 and to evaluate a scoring system to predict IVIG-resistant patients with KD...
  23. pmc Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology
    H P Hartung
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Clin Exp Immunol 158:23-33. 2009
    ..This review covers new developments in these fields and highlights the broad range of potential therapeutic areas in which IVIg may have a clinical impact...
  24. ncbi Increased frequency of alleles associated with elevated tumor necrosis factor-alpha levels in children with Kawasaki disease
    M W Quasney
    Division of Critical Care, Department of Pediatrics, Crippled Children s Foundation Research Center, LeBonheur Children s Medical Center, University of Tennessee, Memphis, Tennessee 38103, USA
    Pediatr Res 49:686-90. 2001
    ..The increased frequency of the high secretor alleles in white children with KD suggests that these loci may be related to susceptibility to KD and to outcome after disease...
  25. pmc Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases
    Ning Li
    Department of Dermatology, University of North Carolina at Chapel Hill, North Carolina 27599, USA
    J Clin Invest 115:3440-50. 2005
    ..These data demonstrate that the therapeutic efficacy of HDIG treatment in the pemphigus and pemphigoid models is dependent on FcRn. Thus, FcRn is a promising therapeutic target for treating such IgG-mediated autoimmune diseases...
  26. ncbi Evidence for the use of intravenous immunoglobulins--a review of the literature
    Shaye Kivity
    Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel
    Clin Rev Allergy Immunol 38:201-69. 2010
    b>Intravenous immunoglobulins (IVIg) were first introduced in the middle of the twentieth century for the treatment of primary immunodeficiencies...
  27. ncbi Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group
    J C Burns
    Department of Pediatrics, University of California, San Diego, School of Medicine, La Jolla 92093 0830, USA
    Pediatr Infect Dis J 17:1144-8. 1998
    ..To determine the prevalence and outcome of intravenous gamma-globulin (IVIG) retreatment in patients with Kawasaki disease (KD)...
  28. ncbi Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency
    Javier De Gracia
    Department of Pneumology, Hospital Universitari Vall d Hebron, Roger de Flor 235 bajos 2 a, 08025 Barcelona, Spain
    Int Immunopharmacol 4:745-53. 2004
    ..Lung damage progression is the most frequent condition in patients with common variable immunodeficiency (CVID). Appropriate immunoglobulin dose adjustments and follow-up guidelines to evaluate this have not been well established...
  29. ncbi No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy
    Philipp O Valko
    Department of Neurology, University Hospital of Zurich, Frauenklinikstrasse 26, Zurich, Switzerland
    J Neurol 255:1900-3. 2008
    We report on four patients with narcolepsy with cataplexy (NC), who were treated with high-dose intravenous immunoglobulins (IVIg)...
  30. ncbi Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG
    Marie Joëlle de Grandmont
    HEMA QUEBEC, Recherche et Developpement, Sainte Foy, Quebec, Canada
    Blood 101:3065-73. 2003
    The therapeutic effects of intravenous immunoglobulins (IVIGs) in several autoimmune diseases are characterized by a decrease in pathologic autoantibody levels...
  31. ncbi Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency
    Paula Jane Busse
    Division of Clinical Immunology, Department of Medicine, The Mount Sinai Medical Center, New York, NY, USA
    J Allergy Clin Immunol 109:1001-4. 2002
    ..The standard treatment, intravenous immunoglobulin (IVIG), has been available for the past 20 years. No large-scale study has compared the incidence of pneumonia in these patients before and after IVIG treatment...
  32. ncbi Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition)
    Mamoru Ayusawa
    Department of Pediatrics, Nihon University School of Medicine, Tokyo 173 8610, Japan
    Pediatr Int 47:232-4. 2005
    ..Major alterations are interpretation of cases with 4 or fewer febrile days shortened by early intravenous immunoglobulin treatment, and the clinical importance of atypical (incomplete, or suspected) cases...
  33. ncbi Serum alanine aminotransferase concentrations in patients with Kawasaki disease
    Ritei Uehara
    Department of Public Health, Jichi Medical School, 3311 1 Yakushiji Minamikawachi, Tochigi 329 0498, Japan
    Pediatr Infect Dis J 22:839-42. 2003
  34. ncbi Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis
    Ales Dudesek
    Department of Neurology, University of Rostock, Gehlsheimer Str 20, 18147, Rostock, Germany
    J Neurol 253:V50-8. 2006
    ..As recently shown IVIG administration right from the early weeks of pregnancy appears to be a promising strategy, but cannot be recommended from the viewpoint of evidence-based medicine...
  35. ncbi Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells
    Thanyalak Tha-In
    Department of Gastroenterology and Hepatology, Erasmus Medical Center University Medical Center, 3015 CE Rotterdam, The Netherlands
    Blood 110:3253-62. 2007
    The modes of action of intravenous immunoglobulins (IVIgs) in exerting their immunomodulatory properties are broad and not fully understood...
  36. ncbi Predictive risk factors for coronary artery abnormalities in Kawasaki disease
    Taeyeun Kim
    Department of Pediatrics, Korea University College of Medicine, Seoul, South Korea
    Eur J Pediatr 166:421-5. 2007
    ..Early identification of IVGG non-responders and active therapeutic intervention for fever in KD cases might decrease the incidence of CAA...
  37. ncbi Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy
    Rolf Fronczek
    J Neurol 254:1607-8. 2007
  38. ncbi High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus
    E Toubi
    Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Haifa, Israel
    Hum Immunol 66:395-402. 2005
    ..However, this needs to be confirmed in double-blind, placebo-controlled studies...
  39. ncbi Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence
    Richard Dodel
    Department of Neurology, Philipps University, Marburg, Germany
    Drugs 70:513-28. 2010
    ..Recently, commercially available intravenous immunoglobulins (IVIG) have been used in small pilot trials for the treatment of patients with AD, based on the ..
  40. ncbi Multifocal motor neuropathy
    E Nobile-Orazio
    Giorgio Spagnol Service of Clinical Neuroimmunology, Dino Ferrari Centre, Department of Neurological Sciences, University of Milan, IRCCS Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122, Milan, Italy
    J Neuroimmunol 115:4-18. 2001
    ..Even if many progresses have been made on the diagnosis and therapy of MMN, there are still several issues on the nosological position, etiopathogenesis and long-term treatment of this neuropathy that need to be clarified...
  41. ncbi Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation
    Eric Aubin
    Department of Research and Development, HEMA QUEBEC, Quebec City, Canada
    Blood 115:1727-34. 2010
    ..Such inhibition of T-cell responses by reducing antigen presentation may therefore contribute to the well-known anti-inflammatory effects of IVIg in autoimmune diseases...
  42. ncbi Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy
    K Kuitwaard
    Department of Neurology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    J Neurol Neurosurg Psychiatry 81:1374-9. 2010
    ..A liquid IVIg preparation is more user friendly and potentially can be infused at a faster rate...
  43. ncbi Differential regulation of myelin phagocytosis by macrophages/microglia, involvement of target myelin, Fc receptors and activation by intravenous immunoglobulins
    Tanja Kuhlmann
    Department of Neuropathology, Charite, Humboldt Universitat, Berlin, Germany
    J Neurosci Res 67:185-90. 2002
    ..Additionally, the effects of intravenous immunoglobulins (IVIg) on this process were investigated...
  44. ncbi Immunoglobulin M-enriched human intravenous immunoglobulins reduce leukocyte-endothelial cell interactions and attenuate microvascular perfusion failure in normotensive endotoxemia
    Johannes N Hoffman
    Department of Surgery, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
    Shock 29:133-9. 2008
    ..Our findings can explain better efficacy of IgM-enriched Igs in patients with severe sepsis...
  45. ncbi High levels of peripheral blood NK cells in women suffering from recurrent spontaneous abortion are reverted from high-dose intravenous immunoglobulins
    Roberto Perricone
    Department of Internal Medicine, University of Rome Tor Vergata, Rome, Italy
    Am J Reprod Immunol 55:232-9. 2006
    To determine the levels of peripheral blood natural killer (NK) cells in healthy women and recurrent aborters, and the effect of intravenous immunoglobulins (IVIGs) on these levels.
  46. ncbi Thrombotic complications after intravenous immunoglobulin therapy in two patients
    Geoffrey G Emerson
    Wilmer Eye Institute, Johns Hopkins Medical Center, Baltimore, Maryland, USA
    Pharmacotherapy 22:1638-41. 2002
    ..We suggest that IVIg may promote thrombosis by increasing blood viscosity, activating platelets, or causing vasospasm and should be administered with caution...
  47. ncbi Cutaneous polyarteritis nodosa treated with intravenous immunoglobulins
    I Lobo
    J Eur Acad Dermatol Venereol 22:880-2. 2008
  48. ncbi Intravenous immunoglobulins, pregnancy and multiple sclerosis
    Christian Confavreux
    European Database for Multiple Sclerosis EDMUS Coordinating Center, Service de Neurologie A, INSERM U433, Hopital Neurologique Pierre Wertheimer, Lyon, France
    J Neurol 251:1138-9. 2004
  49. ncbi Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy
    Peter Kubisz
    National Hemostasis and Thrombosis Center, Clinic of Hematology and Transfusion Medicine, Jessenius Faculty of Medicine of the Comenius University, Faculty Hospital, Martin, Slovakia
    Med Sci Monit 15:CS105-11. 2009
    ..ITI eradicates FVIII inhibitors and allows retreatment with FVIII concentrates in 70% of patients...
  50. ncbi Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective
    Sophie Siberil
    INSERM UMRS 872, Universite Rene Descartes Paris 5, Université Pierre et Marie Curie UPMC Paris 6 75006 Paris, France
    Ann N Y Acad Sci 1110:497-506. 2007
    Initially used for the treatment of immunodeficiencies, intravenous immunoglobulins (IVIg) have increasingly been used as immunomodulatory agents in autoimmune and inflammatory disorders...
  51. ncbi High-dose intravenous immunoglobulins for lupus nephritis--a salvage immunomodulation
    L Rauova
    Department of Medicine B, Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel
    Lupus 10:209-13. 2001
    ..In this review, the clinical and adverse effects, and mechanism of action, with special emphasis on modulation, of idiotypic network is discussed...
  52. ncbi [Indications for intravenous immunoglobulins]
    Luc Mouthon
    Universite Paris Descartes, Faculte de Medecine, Service de Médecine Interne et Centre de Référence pour les Vascularites Nécrosantes et la Sclérodermie Systémique, Hopital Cochin, Assistance Publique Hopitaux de Paris
    Presse Med 35:714-9. 2006
    b>Intravenous immunoglobulins (IgIV) are therapeutic preparations of polyclonal human IgG, obtained from a pool of plasma from more than 1000 healthy donors...
  53. ncbi Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease
    V E A Honkanen
    Division of Rheumatology, Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, Ontario, M5G 1X8, Canada
    Pediatr Cardiol 24:122-6. 2003
    ..We could not distinguish a group at such a low risk that these patients could be left untreated. Young patients with low albumin run a very high risk for CALs...
  54. ncbi Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders
    F Blaes
    Department of Neurology, University of the Saarland, Homburg, Germany
    J Neurol 246:299-303. 1999
    ..We treated four patients suffering from paraneoplastic neurological syndromes with intravenous immunoglobulins. All four had high titers of antineuronal antibodies in serum and CSF...
  55. ncbi Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia
    Ryan J Hansen
    Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA
    Blood 100:2087-93. 2002
    ..This model of ITP will be useful for further investigations of IVIG mechanism of action and for development of new therapies for ITP...
  56. ncbi Activation of cryptic IgG reactive with BAFF, amyloid beta peptide and GM-CSF during the industrial fractionation of human plasma into therapeutic intravenous immunoglobulins
    Isabelle St-Amour
    Department of Research and Development, HEMA QUEBEC, Quebec QC, Canada G1V 5C3
    Clin Immunol 133:52-60. 2009
    ....
  57. ncbi Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines
    M C Dalakas
    Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Building 10, Room 4N248, 10 Center Drive MSC 1382, Bethesda, Maryland 20892 1382, USA
    Muscle Nerve 22:1479-97. 1999
    ..Finally, safety issues, risk factors, adverse reactions, spurious results or serological tests, and practical guidelines associated with the administration of IVIg in the treatment of neuromuscular disorders are presented...
  58. ncbi Alteration of biochemical profiles after high-dose intravenous immunoglobulin administration in Kawasaki disease
    K Y Lee
    Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
    Acta Paediatr 91:164-7. 2002
    ..Total cholesterol and triglyceride increased slightly after 7 d. A significant decrease in HDL-cholesterol and C-reactive protein was seen 2 h and 24 h after IVIG treatment...
  59. pmc Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis
    Y Levy
    Department of Medicine B and the Centre for Autoimmune Diseases, Sheba Medical Centre Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Israel
    Ann Rheum Dis 62:1221-3. 2003
    ..Peripheral neuropathy is a prominent feature of the systemic and secondary vasculitides. Usually, it is responsive to corticosteroids, but in certain cases it may be resistant to corticosteroid or immunosuppressive treatment, or both...
  60. ncbi Epidemiologic study of Kawasaki disease at a single hospital in Daejeon, Korea (1987 through 2000)
    Kyung Yil Lee
    Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
    Pediatr Infect Dis J 23:52-5. 2004
    ..We evaluated the epidemiology and a range of clinical characteristics in children with Kawasaki disease (KD) in one area of South Korea...
  61. pmc Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study
    F Nacci
    Department of Medicine and Surgery, University of Florence, Italy
    Ann Rheum Dis 66:977-9. 2007
    In systemic sclerosis (SSc), joint involvement may reduce the functional capacity of the hands. Intravenous immunoglobulins have previously been shown to benefit patients with SSc.
  62. ncbi Epidermolysis bullosa acquisita: treatment with intravenous immunoglobulins
    K Gourgiotou
    Department of Dermatology, University of Athens, A Sygros Hospital, Greece
    J Eur Acad Dermatol Venereol 16:77-80. 2002
    ..The treatment was well tolerated and the results were satisfactory. It seems that IVIg, due to its possible immunomodulatory mode of action, can be an efficacious therapeutic agent in this rare autoimmune disease...
  63. ncbi Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg)
    Stephan von Gunten
    Institute of Pathology, University Hospital Basel, Basel, Switzerland
    Autoimmun Rev 7:453-6. 2008
    Human intravenous immunoglobulins (IVIg) contain natural autoantibodies against the inhibitory lectin-receptors Siglec-8 and Siglec-9. These two members of the Siglec family are known to mediate both inhibitory and death signals...
  64. pmc Identification of a receptor required for the anti-inflammatory activity of IVIG
    Robert M Anthony
    The Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 105:19571-8. 2008
    ..These studies thus identify an antibody receptor specific for sialylated Fc, and present the initial step that is triggered by IVIG to suppress inflammation...
  65. ncbi IV immunoglobulin does not reverse established weakness in MS
    J H Noseworthy
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 55:1135-43. 2000
    ..Immunoglobulin (Ig) administration induces remyelination in the Theiler's virus model of MS...
  66. ncbi A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis
    J H Noseworthy
    Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Neurology 56:1514-22. 2001
    ..To determine whether IV immunoglobulin (IVIg) reverses chronic visual impairment in MS patients with optic neuritis (ON)...
  67. ncbi Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease
    Tohru Kobayashi
    Department of Pediatrics and Developmental Medicine, Gunma University Graduate School of Medicine, Gunma 377 8511, Japan
    Circulation 113:2606-12. 2006
    ..In the present study, we developed models to predict unresponsiveness to intravenous immunoglobulin (IVIG) in Kawasaki disease (KD)...
  68. ncbi Multifocal motor neuropathy
    Jan Thies H van Asseldonk
    Department of Clinical Neurophysiology, Neuromuscular Research Group, Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, Netherlands
    Lancet Neurol 4:309-19. 2005
    ....
  69. ncbi Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells
    Vinayakumar Siragam
    Canadian Blood Services, 1800 Alta Vista Drive, Ottawa, Ontario, K1G 4J5, Canada
    Nat Med 12:688-92. 2006
    ..In conclusion, the clinical effects of IVIg in ameliorating ITP seem to involve the acute interaction of IVIg with activating Fc gammaR on dendritic cells...
  70. ncbi Initial intravenous gammaglobulin treatment failure in Kawasaki disease
    C A Wallace
    Department of Pediatrics, University of Washington and Children s Hospital and Regional Medical Center, Seattle, Washington 98105 0371, USA
    Pediatrics 105:E78. 2000
    ....
  71. ncbi Management of immune thrombocytopenic purpura in adults
    Roberto Stasi
    Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy
    Mayo Clin Proc 79:504-22. 2004
    ..We describe a logical and structured approach to the clinical management of ITP in adults, based on a literature review and our personal experience...
  72. ncbi Infliximab as a novel therapy for refractory Kawasaki disease
    Jennifer E Weiss
    Division of Pediatric Cardiology, Department of Pediatrics, Schneider Children s Hospital, North Shore Long Island Jewish Medical Center, New Hyde Park, New York 11040, USA
    J Rheumatol 31:808-10. 2004
    ..v.IG and methylprednisolone, who was treated with infliximab. After the first dose he defervesced and his laboratory measures improved...
  73. ncbi Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature
    David Hefer
    Department of Internal Medicine, St Luke s Roosevelt Hospital Center, 1000 Tenth Avenue, 10019, New York, NY, USA
    Ann Hematol 83:661-5. 2004
    ..Ten patients out of the 29 reported patients died from this serious complication. In our patient, spontaneous reperfusion occurred without any treatment and he had an uneventful outcome...
  74. ncbi Lack of effect of intravenous immunoglobulins on tics: a double-blind placebo-controlled study
    Pieter J Hoekstra
    Child and Adolescent Psychiatry Center, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
    J Clin Psychiatry 65:537-42. 2004
    ..No data are available on the effectiveness of intravenous immunoglobulins (IVIG) on tic severity in unselected tic disorder patients.
  75. ncbi Adverse effects of treatment with intravenous immunoglobulins for neurological diseases
    Matthias Wittstock
    Dept of Neurology, University of Rostock, Gehlsheimer Str 20, 18147, Rostock, Germany
    J Neurol 253:V75-9. 2006
    Therapy with intravenous immunoglobulins (IVIg) is considered to be a safe treatment for a number of immune-mediated neurological diseases. Published data about prevalence of adverse effects range from 11 to 81%...
  76. ncbi A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease
    Takaomi Minami
    Department of Pediatrics, Wakayama Medical University, Wakayama, Japan
    J Pediatr 147:78-83. 2005
    ..To investigate whether reduced levels of plasma platelet-activating factor acetylhydrolase (PAF-AH) as a result of a genetic polymorphism are involved in the pathogenesis of Kawasaki disease (KD)...
  77. ncbi Drug Insight: the use of intravenous immunoglobulin in neurology--therapeutic considerations and practical issues
    Ralf Gold
    Department of Neurology at St Josef Hospital, University of Bochum, Germany
    Nat Clin Pract Neurol 3:36-44. 2007
    ..In this article, we review the current indications for IVIg treatment, address practical issues related to the use and costs of the drug, and summarize its mechanisms of action...
  78. ncbi The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile
    Marinos C Dalakas
    Neuromuscular Diseases Section, National Institute of Neurological Diseases and Stroke, National Institutes of Health, MSC 1382, Room 4N248, Building 10, 10 Center Drive, Bethesda, MD 20892 1382, USA
    Pharmacol Ther 102:177-93. 2004
    ..v.Ig with other immunosuppressive drugs...
  79. pmc The involvement of Fc gamma receptor gene polymorphisms in Kawasaki disease
    M Biezeveld
    Emma Children s Hospital, Academic Medical Centre AMC, University of Amsterdam, Amsterdam, The Netherlands
    Clin Exp Immunol 147:106-11. 2007
    ..Therapy consists of intravenous immunoglobulins (IVIG), leading to a decrease of complications to 5-16%...
  80. ncbi Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial
    R van Koningsveld
    Department of Neurology, Erasmus MC, Rotterdam, Netherlands
    Lancet 363:192-6. 2004
    ..Our aim was to assess whether methylprednisolone, when taken with IVIg, improves outcome when compared with IVIg alone...
  81. ncbi High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin
    A Rutter
    Department of Dermatology, University of Munster, Germany
    J Am Acad Dermatol 44:1010-24. 2001
    Adjuvant high-dose intravenous immunoglobulins (IVIgs) are being used increasingly in a range of immune-mediated and autoimmune diseases...
  82. pmc Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases
    S V Kaveri
    INSERM U28, Paris, France
    Clin Exp Immunol 86:192-8. 1991
    ..This overview briefly discusses the current use of IVIg in human autoimmune diseases with a particular emphasis on the possible mechanisms by which IVIg could suppress pathological autoimmune responses...
  83. ncbi F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins
    Milan Basta
    Neuronal Excitability Section, National Institute for Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA
    Nat Med 9:431-8. 2003
    ..This binding could interfere with the role of C3a and C5a in inflammation...
  84. ncbi Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor
    A Samuelsson
    Laboratory of Molecular Genetics and Immunology, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Science 291:484-6. 2001
    ..Modulation of inhibitory signaling is thus a potent therapeutic strategy for attenuating autoantibody-triggered inflammatory diseases...
  85. ncbi Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy
    Derin B Keskin
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA, USA
    Cytokine 41:315-21. 2008
    ..The conclusions from this limited number of patients, prospectively studied, would suggest that both CIST and IVIg therapies are similar in their ability to influence a panel of cytokines in patients with pemphigus vulgaris...
  86. ncbi Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg)
    Denis Glotz
    Department of Nephrology, INSERM U 430, Hĵpital Européen Georges Pompidou, Paris, France
    Am J Transplant 2:758-60. 2002
    ..We have shown that administration of intravenous immunoglobulins (IVIg) can induce a profound and sustained decrease in the titers of anti-HLA antibodies...
  87. ncbi Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome
    Brigitte Buchwald
    Department of Neurology, Julius Maximilians Universitat, Josef Schneider Strasse 11, 97080 Wurzburg, Germany
    Ann Neurol 51:673-80. 2002
    ..Therapeutic IVIg is capable of neutralizing neuromuscular blocking antibodies in GBS by a dose-dependent, antibody-mediated mechanism. This may, in part, explain its therapeutic efficacy...
  88. ncbi Kawasaki disease: etiology, pathogenesis, and treatment
    Karyl S Barron
    Division of Intramural Research, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA
    Cleve Clin J Med 69:SII69-78. 2002
  89. pmc Risk factors for failure of initial intravenous immunoglobulin treatment in Kawasaki disease
    Sungho Cha
    Department of Pediatrics, College of Medicine, Kyunghee University Hospital, Dongdaemun Gu, Seoul, Korea
    J Korean Med Sci 23:718-22. 2008
    ..There is a need for a prospective study focused on baseline hepatobiliary parameters...
  90. ncbi Immune thrombocytopenic purpura
    Douglas B Cines
    Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, USA
    N Engl J Med 346:995-1008. 2002
  91. ncbi Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside
    G Zandman-Goddard
    Department of Medicine C, Wolfson Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Lupus 18:884-8. 2009
    ..Hence, extractable IVIg that is directed to the specific pathogenic immunoglobulins will enable the more specific therapy for patients with lupus...
  92. pmc The antiinflammatory activity of IgG: the intravenous IgG paradox
    Falk Nimmerjahn
    Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY 10021, USA
    J Exp Med 204:11-5. 2007
    ..Here we propose that these Fc-sialylated IgGs engage a unique receptor on macrophages that, in turn, leads to the upregulation of an inhibitory Fcgamma receptor (FcgammaR), thereby protecting against autoantibody-mediated pathology...
  93. ncbi High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases
    Sonia Segura
    Department of Dermatology, Hospital Clinic, Barcelona, Spain
    J Am Acad Dermatol 56:960-7. 2007
    ..Recently, high-dose intravenous immunoglobulin (IVIg) has been employed in selected cases, with excellent results in most of them...
  94. pmc Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy
    Björn Tackenberg
    Department of Neurology, Clinical Neuroimmunology Group, Philipps University, 35039 Marburg, Germany
    Proc Natl Acad Sci U S A 106:4788-92. 2009
    ....
  95. ncbi Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease
    Hiroshi Tsujimoto
    Department of Pediatrics, National Defense Medical College, Tokorozawa, Saitama 359 8513, Japan
    Clin Immunol 103:161-8. 2002
    ..As a result, the present study demonstrated a novel action in which high-dose IVIg therapy decreased the number of circulating neutrophils by accelerating their apoptosis in KD...
  96. ncbi Impairment of angiogenic activity in the serum from patients with coronary aneurysms due to Kawasaki disease
    Kouji Higashi
    Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan
    Circ J 71:1052-9. 2007
    ..We hypothesized that serum activity to stimulate in vitro human umbilical vein endothelial cells (HUVEC) tube formation might be impaired in KD...
  97. ncbi The product: All intravenous immunoglobulins are not equivalent
    Jerry Siegel
    Department of Pharmacy, Ohio State University Medical Center, Columbus, Ohio 43210, USA
    Pharmacotherapy 25:78S-84S. 2005
    ..Convenience factors must be considered, for both the health care provider and the patient, without jeopardizing the more important features of the IGIV, such as tolerability and safety...
  98. ncbi Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy
    Michel Lecendreux
    J Sleep Res 12:347-8. 2003
  99. ncbi Mechanisms of action of intravenous immunoglobulins
    Anne Baerenwaldt
    Department of Biology, Institute of Genetics, University of Erlangen Nuremberg, Staudtstr 5, 91058 Erlangen, Germany
    Expert Rev Clin Immunol 6:425-34. 2010
    ..This review will discuss which molecular and cellular pathways might be involved in the anti-inflammatory activity of IVIg and for which types of autoimmune diseases they might be relevant...
  100. ncbi Early treatment with intravenous immunoglobulin in patients with Kawasaki disease
    Shirley M L Tse
    Division of Rheumatology and Cardiology, Department of Pediatrics, Hospital for Sick Children, Hospital for Sick Children Research Institute, University of Toronto, Ontario, Canada
    J Pediatr 140:450-5. 2002
    ....
  101. ncbi Intravenous immunoglobulins contain naturally occurring antibodies that mimic antineutrophil cytoplasmic antibodies and activate neutrophils in a TNFalpha-dependent and Fc-receptor-independent way
    Sven Jarius
    Institute of Clinical Neuroimmunology, Ludwig Maximilians University, Munich, Germany
    Blood 109:4376-82. 2007
    ....

Research Grants68

  1. PEDIATRIC AND MATERNAL HIV STUDIES COORDINATING CENTER
    CAROL NESEL; Fiscal Year: 2012
    ..k. ..
  2. PEDIATRIC AND MATERNAL HIV STUDIES COORDINATING CENTER
    CAROL NESEL; Fiscal Year: 2011
    ..k. ..
  3. PEDIATRIC AND MATERNAL HIV STUDIES COORDINATING CENTER
    CAROL NESEL; Fiscal Year: 2010
    ..k. ..
  4. PEDIATRIC AND MATERNAL HIV STUDIES COORDINATING CENTER
    CAROL NESEL; Fiscal Year: 2009
    ..k...
  5. IMMUNOTHERAPY IN PEDIATRIC CEREBRAL MALARIA
    Terrie Taylor; Fiscal Year: 1991
    ..Children at highest risk of dying or developing brain damage can now be identified. A total 60 IVIG recipients and 60 controls will be required to detect a decrease in mortality from 50 percent to 25 percent...
  6. HIV-IG FOR PREVENTION OF VERTICAL TRANSMISSION
    JAY JACKSON; Fiscal Year: 2003
    ..2. Evaluate the differences in clinical progression to AIDS, the decline in CD4 counts, and survival at 2.5 years in the HIV-1 infected infants who received HIVIG or IVIG. ..
  7. Statistical Methods for Clinical Trials with Twin Births
    Michele Shaffer; Fiscal Year: 2007
    ..Thus, the effects of trial design and analysis need to be quantified and taken into consideration for studies that involve singletons and twin births. [unreadable] [unreadable] [unreadable] [unreadable]..
  8. Naturally occurring T regulatory cells control airway hyperresponsiveness
    Erwin Gelfand; Fiscal Year: 2008
    ..abstract_text> ..
  9. MEKK2 Regulation of Mast Cell/T Cell Cytokine Production
    Erwin Gelfand; Fiscal Year: 2003
    ..The studies will also define MEKK2 and ERK5 as targets for drug discovery for the control of allergic inflammation. ..
  10. FcR Enhanced Ag Presentation--Induction Tumor Immunity
    Raphael Clynes; Fiscal Year: 2006
    ..3) Determine whether FcgammaR uptake enhances class I antigen presentation in human systems and specifically whether antibody-mediated T cell priming occurs in Trastuzumab-treated patients. ..
  11. PHAGOCYTOSIS IN PULMONARY ALVEOLAR MACROPHAGES
    Raphael Clynes; Fiscal Year: 2009
    ....
  12. Pathogenic Role of Islet Cell Abs in Autoimmune Diabetes
    Raphael A Clynes; Fiscal Year: 2010
    ..We propose in Aim 3 to extend this work to test relevance to the antibody-mediated cross-presentation of insulin, an antigen of singular importance to diabetes. ..
  13. OCULAR PEMPHIGOID--MECHANISM OF PATHOGENESIS
    A Ahmed; Fiscal Year: 2001
    ..The immediate clinical impact of this research will be the generation and availability of highly specific and sensitive serological laboratory test for the early diagnosis of OCP. ..
  14. Fibrogenic factors in ocular cicatricial pemphigoid
    A Ahmed; Fiscal Year: 2004
    ..The studies have significant therapeutic potential. The identified molecules or portion of processes that mediate could be blocked or arrested, and this may result in cessation of disease progression and, prevention of blindness. ..
  15. Interleukin 1alpha polymorphism and Alzheimer's disease
    Yansheng Du; Fiscal Year: 2004
    ..abstract_text> ..
  16. MR PREDICTORS OF RESPONSE TO HAART IN HIV DEMENTIA
    Joseph Berger; Fiscal Year: 2004
    ..It will also open novel avenues for exploring the differential sensitivities of these pathways to HAART, and suggest unique therapeutic options. ..
  17. JCV Virus Expression in Oropharynx and HIV
    Joseph Berger; Fiscal Year: 2004
    ..This line of investigation would add credence to an oropharyngeal mechanism of JCV transmission and may ultimately lead to the clinical identification of an acute illness attributable to this pathogen. ..
  18. PEMPHIGUS 2005-PROGRESS AND FUTURE DIRECTIONS
    Jean Claude Bystryn; Fiscal Year: 2005
    ..We expect it will attract 100-150 scientists and clinicians dedicated to investigate and treating pemphigus. ..
  19. ICAM1 gene inactivation protects against ischemic injury
    Robert Montgomery; Fiscal Year: 2006
    ..This work has important implications for the selective inactivation of gene function in allografts through ex vivo gene transfer. ..
  20. 2003 CIS Summer School
    Charlotte Cunningham Rundles; Fiscal Year: 2003
    ..The participants will be drawn from training programs, hospitals and institutions that are in North, Central or South America. Only fellows from the United States will receive funding made possible through the NIH grant. ..
  21. VLA4 IN CTL MEDIATED ISLET ALLOGRAFT REJECTION
    Mark Stegall; Fiscal Year: 2001
    ..The approach may lead to novel forms of immune suppression that may benefit not only islet transplantation, but also other types of organ allografts. ..
  22. NEUROSCIENCE OF HIV CONFERENCE
    Joseph Berger; Fiscal Year: 2002
    ..Dr. Brian Wigdahl, international co-chair of the ISNV, is a co-investigator on this grant. ..
  23. POLYVALENT VACCINE IN IL-2+GM-CSF LIPOSOMES FOR MELANOMA
    Jean Claude Bystryn; Fiscal Year: 2004
    ..More broadly, it may provide a general method of potentiating the immunogenicity of vaccines against other cancers and to infectious diseases. ..
  24. Primary Immune Deficiency Consortium Conference
    Charlotte Cunningham Rundles; Fiscal Year: 2008
    ..Principle topics will focus on: Diagnosis of Immunodeficiency; Genetics, Immune Reconstruction, and the Use of Standard and Novel Therapies. ..
  25. SERUM CYT-MAA AS AN EARLY MARKER OF RESPONSE TO THERAPY IN RESECTED MELANOMA
    Jean Claude Bystryn; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  26. Primary Immunne Deficiency Consortium Conference
    Charlotte Cunningham Rundles; Fiscal Year: 2005
    ..Principle topics will focus on: Antibody Deficiency; Combined Immune Defects; Neutrophil Disorders; Laboratory Evaluation of Primary Immunodeficiency; Immune Reconstiution, and the Use of Standard and Novel Therapies. ..
  27. HIV Neuroprotection Workshop
    Joseph Berger; Fiscal Year: 2004
    ..The proposed conference is the first of its kind to highlight neuroprotection in HIV CNS and PNS disorders. By coupling this meeting with the International Symposium on Neurovirology this synergy can be exploited. ..
  28. 2002 Summer School in Primary Immunodeficiency Disorders
    Charlotte Cunningham Rundles; Fiscal Year: 2002
    ..Fellows participating in the course will be reimbursed for their travel expenses. No registration fee will be charged for the fellows participating in the program. ..
  29. Bone Marrow Angioblasts For Cardiac Regeneration
    Silviu Itescu; Fiscal Year: 2004
    ....
  30. MECHANISMS OF IL-2 IMMUNE ENHANCEMENT IN HUMANS
    Charlotte Cunningham Rundles; Fiscal Year: 2001
    ..Thus, this application will focus on the cellular and molecular mechanisms by which IL-2 reconstitutes T cell immunity in this model system. ..
  31. Reconstitution of Protective CMV Immunity and Immune Regulation After HAART
    Adriana Weinberg; Fiscal Year: 2008
    ..These analyses will define the role of TREG in the inadequate CMV immune reconstitution of HAART recipients. [unreadable] [unreadable] [unreadable] [unreadable]..
  32. Proteolytic Antibody HIVcides
    Sudhir Paul; Fiscal Year: 2007
    ..These studies may identify proteolytic antibodies suitable for further development as a topical HIVcide. [unreadable] [unreadable] [unreadable]..
  33. Oral Delivery of DNA Vaccines
    FRANK ORSON; Fiscal Year: 2003
    ....
  34. Protection of Mice From Lethal Alphavirus Encephalitis
    David N Irani; Fiscal Year: 2010
    ....
  35. ANTI-HIV ANTIBODY IMMUNOTHERAPY IN HUPBL-SCID
    Dennis Burton; Fiscal Year: 2001
    ..The emerging results should assist in the design of immunotherapeutic strategies using neutralizing antibodies and illuminate areas of potential concern such as neutralization escape. ..
  36. PATHOGENESIS OF THROMBOCYTOPENIAS OF NEONATES
    Robert Christensen; Fiscal Year: 2002
    ..This approach is essential to improve the care of the large number of NICU patients affected with these two common varieties of thrombocytopenia. ..
  37. TRAINING GRANT IN MOLECULAR CARDIOLOGY
    Mark Entman; Fiscal Year: 2008
    ..This integrated design has consistently proven to be effective in providing successful independent and competitive investigators in molecular biology of cardiovascular medicine. ..
  38. RECOMBINANT SINGLE DOMAIN & HYBRID PEPTIDASE ANTIBODIES
    Sudhir Paul; Fiscal Year: 2002
    ....
  39. Genetic Markers and gene expression in Kawasaki Disease
    Jane C Burns; Fiscal Year: 2010
    ..This project will build on previous work to understand the genetic basis for susceptibility to KD and its complications, which will lead to new insights into therapeutics and disease prevention. ..
  40. Brain Atrophy/Diffusion Tensor Study/Multiple Sclerosis
    Robert Fox; Fiscal Year: 2008
    ..Furthermore, these studies should help develop improved methods for evaluating new therapeutic strategies for neuroprotection and neuroregeneration. ..
  41. Detection of Biofilm Bacteria using GloBac
    Robin Patel; Fiscal Year: 2008
    ..The goal of the proposed studies is to develop a rapid test for detection of bacteria on artificial joints that can be used in the operating room to diagnose infected artificial joints. [unreadable] [unreadable] [unreadable]..
  42. AAV Gene Therapy for Alzheimer's Disease
    David Morgan; Fiscal Year: 2009
    ..The outcome of these studies will, hopefully, be a novel gene therapeutic approach to dismantle the catastrophe of Alzheimer's dementia. ..
  43. Novel Strategies for Y pestis Immunotherapy
    Jeffrey Ravetch; Fiscal Year: 2003
    ..pestis mutants defective in virulence. This approach will thus permit the evaluation of the interaction of the pathogen with adaptive immune pathways by bypassing the effects on innate responses. ..
  44. Development of Autoimmunity During Puberty in SLE
    KATHLEEN O NEIL; Fiscal Year: 2007
    ..The data from this study will allow us to estimate sample size and perform power analyses for a larger study utilizing all CARRA centers. [unreadable] [unreadable]..
  45. Pharmacogenetics in Tourette Syndrom
    Harvey Singer; Fiscal Year: 2004
    ..The identification of genetic polymorphisms that are associated with clinical disease or treatment success, has obvious benefits. ..
  46. 8th International Kawasaki Disease Symposium
    Jane Burns; Fiscal Year: 2005
    ....
  47. High dose erythropoietin for neonates with asphyxia
    Robert Christensen; Fiscal Year: 2004
    ..To aid the design of a subsequent Phase III trial, neurodevelopmental outcome will be measured in the EIP program clinics at six and 12 months or life. ..
  48. Molecular Characterization of a Human Dysfibrinogen
    VERONICA FLOOD; Fiscal Year: 2005
    ..This study will provide valuable information about the structural and functional behavior of this dysfibrinogen and will ultimately improve understanding of clot formation and the process of hemostasis. ..
  49. Robotic Preparation of cDNA Single Cells
    William Cleveland; Fiscal Year: 2006
    ..In summary, we believe that an instrument which couples multidimensional microscopy with DNA array technology will be a spectacular tool that will be useful to many laboratories. ..
  50. PTS1 Regulation of Brain Met Enk Levels in Alcoholism
    William Banks; Fiscal Year: 2004
    ..abstract_text> ..
  51. VIRAL EVASION AND HIV ENTRY-BLOCKING STRATEGIES
    Dennis Burton; Fiscal Year: 2004
    ..The studies will reveal how HIV-1 can evade entry-blocking strategies, and may provide important information for vaccine design. ..
  52. Pregnancy and the Modulation of Multiple Sclerosis
    Annette Langer Gould; Fiscal Year: 2006
    ..The search for the pregnancy-related factor or hormone responsible for the protective effect of pregnancy in MS may potentially lead to the development of novel treatments for MS and other Th1-driven autoimmune diseases. ..
  53. Opiate Addiction and HIV-1 Induced Release of Cytokines
    William Banks; Fiscal Year: 2006
    ....
  54. Endotoxin-induced Uveitis Revisited
    James T Rosenbaum; Fiscal Year: 2010
    ..Future studies can buil d on these observations to test anti-inflammtory molecules induced by endotoxin as these molecules are potentially useful in the treatment of uveitis and other inflammations. ..
  55. STUDY OF FC RECEPTOR GENES: MACROPHAGES AND LYMPHOCYTES
    Jeffrey Ravetch; Fiscal Year: 2007
    ..unreadable]..
  56. BAYESIAN METHODS IN BIOSTATISTICS
    Joel Greenhouse; Fiscal Year: 2002
    ..Yet, despite great progress in the use of these models, fundamental issues remain, as we explain below, this is the main motivation of our work. ..
  57. beta-Amyloid Antibodies with Specific Proteolytic Activity
    Sudhir Paul; Fiscal Year: 2008
    ..Proteolytic anti-Abeta Abs capable of preventing the deposition of Abeta and cognitive decline would be candidates for passive immunotherapy of humans with AD. ..
  58. INNATE AND Ag-ADAPTED CHEMICALLY REACTIVE ANTIBODIES
    Sudhir Paul; Fiscal Year: 2003
    ..Successful execution of this project will provide insight to the genesis of chemically reactive Abs and potentially validate the use CRAs for inhibition and induction of antigen-specific catalytic Abs. ..
  59. gp120 covalent analogs as candidate HIV vaccines
    Sudhir Paul; Fiscal Year: 2008
    ..Novel vaccination strategies and HIV-1 neutralizing Abs will emerge from these studies if the physiological barriers to catalytic Ab synthesis can be bypassed. [unreadable] [unreadable]..
  60. CATALYTIC ANTIBODIES FOR TUMOR IMMUNOTHERAPY
    Sudhir Paul; Fiscal Year: 2001
    ..The investigators expect the proposed studies to generate catalytic Fv constructs capable of permanent and efficient inactivation of EGFR, and to establish the validity of using catalytic Abs for tumor immunotherapy. ..
  61. BEHAVIORAL INTERVENTION FOR CONGENITAL CMV DISEASE
    Stuart Adler; Fiscal Year: 2001
    ..The results of this trial will determine the effectiveness of behavioral intervention and the motivation necessary to adhere to recommendations and prevent child-to-mother transmission of CMV. ..
  62. 10th International CMV Workshop
    Stuart Adler; Fiscal Year: 2005
    ..The purpose is to keep everybody up to date and current about what's going on in all areas and stimulate new research projects and collaborations. We anticipate between 300 and 500 attendees. ..
  63. EPIDEMIOLOGY OF CMV
    Stuart Adler; Fiscal Year: 2007
    ..The results of this study will establish if immunization of mothers against CMV infection is possible. ..
  64. Prevention of Cytomegalovirus Infection
    Stuart Adler; Fiscal Year: 2007
    ..The results of this study will establish if prevention of CMV infections is possible. [unreadable] [unreadable]..